At the BIO meeting in Atlanta (May 18-21), the Chairman of Datapharm Australia Pty Ltd, Dr Helen Allars, signed an agreement with Mark Richardson, Managing Director of Phoenix Eagle Company Pty Ltd, based in Western Australia, to conduct the first randomized clinical trial of its OPAL A papaya product in healing venous and pressure ulcers.  The randomized study will be conducted in Melbourne with a key opinion leader in the field of wound healing, Associate Professor Michael Woodward, as Principal Investigator.  Datapharm’s medical director, Dr Lynette Tozer, has recently commenced writing up the case histories of the use of the papaya product in the treatment of chronic pressure ulcers in quadriplegic patients at an Australian hospital. Her initial observations indicate that this natural product has the potential to become a significant wound healing medicine.